Determination of methotrexate in human urine at trace levels by solid phase extraction and high‐performance liquid chromatography/tandem mass spectrometry

Laboratory of Environmental Hygiene and Industrial Toxicology, Salvatore Maugeri Foundation, via Alzaia 29, Pavia, Italy.
Rapid Communications in Mass Spectrometry (Impact Factor: 2.25). 02/2000; 14(3):173-9. DOI: 10.1002/(SICI)1097-0231(20000215)14:3<173::AID-RCM862>3.0.CO;2-K
Source: PubMed

ABSTRACT For biological monitoring of hospital personnel occupationally exposed to antineoplastic agents, highly sensitive and specific methods are required. In order to detect trace MTX urinary concentrations, a precise and accurate high-performance liquid chromatography/tandem mass spectrometry (HPLC-MS/MS) procedure, incorporating solid phase extraction, has been developed. Urine samples were purified by solid phase extraction (SPE) on octadecyl bonded, endcapped silica SPE columns. After eluting with methanol, the solvent was evaporated obtaining a 25-fold concentration of the analyte. This procedure was validated by using 7-OHMTX as internal standard. Calibration curves had correlation coefficients always higher than 0.999, and the limit of detection was assessed at 0.2 microg L(-1). High specificity of the HPLC-MS/MS technique assures that no interfering substances are detected rather than the analyte of interest.

Download full-text


Available from: Christina Sottani, Sep 28, 2015
58 Reads
  • Source
    • "and with various purposes, ranging from quality control to clinical pharmacokinetics and therapeutic drug monitoring [1] [12] [13]. Among these methods, a variety of chromatographic conditions have been described, including acidic or neutral mobile phase and UV, fluorimetry or mass spectrometry detection [1] [14] [15]. Likewise, standard analytical methodologies based on LC with UV detection are described in the main Pharmacopoeias for MTX as raw material [16] [17] [18] or injectable preparation [17] [18]. "
    01/2015; 2(2):59-67. DOI:10.14205/2309-4435.2014.02.02.3
  • Source
    • "It should be noted that these procedures do not require any derivatization process . In addition, the on-line chromatographic analysis with mass-selective detection allows trace determination of the analytes (Minoia et al., 1998; Sottani et al., 1998; Turci et al., 2000a,b). Urinary Table 1 Anticancer drugs classified according to the IARC (last update: "
    [Show abstract] [Hide abstract]
    ABSTRACT: A sensitive, specific, accurate and reproducible high-performance liquid chromatography (HPLC) analytical method was developed and validated for the quantification of the novel oral taxane analogue BAY59-8862 in mouse plasma and tissue samples. A fully automated solid-phase extraction procedure was applied to the plasma after internal standard (IS) addition, with only 0.2 mL volume of the sample loaded on a CN-Sep-pak cartridge. In the case of the tissues a very simple acetonitrile extraction was used to recover BAY59-8862 and its internal standard from liver. The procedure for the quantification of BAY59-8862 and its IS (IDN5127) is based on high-performance liquid chromatography/ion spray-tandem mass spectrometry, operating in selected ion monitoring mode. The retention times of BAY and IS were 7.21 and 10.36 min, respectively. In both plasma and tissue specimens the assay was linear in the range 50-5000 ng/mL (ng/g). The overall precision and accuracy were assessed on three different days. The results for plasma were within 6.1% (precision) and between 99 and 112% (accuracy), and for the liver samples within 7.3% and between 104 and 118%, respectively. The LOD was 5 ng/mL and 20 ng/g in the plasma and liver, respectively. In addition, the biliary excretion of the compound in rats was studied. The study showed that an oxidative chemical reaction was the preferred metabolic pathway for biliary excretion, and two sets of mono- and dihydroxylated metabolites were detected by LC/ISP-MS/MS experiments. With this method, BAY59-8862 pharmacokinetic was determined in mice. The combined results demonstrate that the methodology can be considered a valid approach to conduct pharmacokinetic and metabolic studies during preclinical and clinical investigations.
    Rapid Communications in Mass Spectrometry 10/2001; 15(19):1807-16. DOI:10.1002/rcm.438 · 2.25 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In order to assess exposure levels of hospital personnel involved in the preparation and administration of antineoplastic drugs, environmental monitoring should be carried out. Wipe samples, pads, gloves and air samples should be collected at the end of each work shift, properly treated and then analysed using instrumental techniques which are sufficiently sensitive and specific to detect even trace amounts of drug. In this study, a method using high performance liquid chromatography/tandem mass spectrometry (HPLC/MS/MS), incorporating solid phase extraction (SPE), was validated for determination of methotrexate (MTX) in wipe and air samples. Each step of the method was first developed and optimised using ultraviolet detection (UV), and afterwards tandem mass spectrometry was used to obtain a lower limit of quantitation when the expected drug level was less than the analytical UV detection limit. SPE enabled a 20-fold preconcentration of the analyte when using HPLC/UV and a further 30-fold preconcentration was obtained when analysing samples by HPLC/MS/MS. For example, the limit of quantitation (LLQ) was lowered from 3000 ng on wipe (direct injection onto an HPLC/UV system) to 5 ng on wipe (SPE plus HPLC/MS/MS). 7-hydroxymethotrexate was used as internal standard to assess precision and accuracy.
    Rapid Communications in Mass Spectrometry 04/2000; 14(8):685-91. DOI:10.1002/(SICI)1097-0231(20000430)14:8<685::AID-RCM937>3.0.CO;2-2 · 2.25 Impact Factor
Show more